{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:46:41Z","timestamp":1775191601368,"version":"3.50.1"},"reference-count":13,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,26]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>The molecular events leading to primary and acquired resistance to ibrutinib in marginal zone lymphoma have not been studied. We describe the first case of MZL with acquired resistance to ibrutinib in which mutations in both BTK (C481S) and PLCG2 are documented.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018029058","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T21:45:38Z","timestamp":1550094338000},"page":"500-502","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Resistance mechanism for ibrutinib in marginal zone lymphoma"],"prefix":"10.1182","volume":"3","author":[{"given":"Narendranath","family":"Epperla","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arwa Y.","family":"Shana\u2019ah","sequence":"additional","affiliation":[{"name":"Deparment of Pathology, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Jones","sequence":"additional","affiliation":[{"name":"Deparment of Pathology, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth A.","family":"Christian","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabarish","family":"Ayyappan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kami","family":"Maddocks","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2019,2,13]]},"reference":[{"issue":"16","key":"2020021108322653400_B1","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2020021108322653400_B2","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"2020021108322653400_B3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood-2015-03-585075","article-title":"Targeted therapies in CLL: mechanisms of resistance and strategies for management","volume":"126","author":"Woyach","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2020021108322653400_B4","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"1","key":"2020021108322653400_B5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom\u2019s Macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"issue":"22","key":"2020021108322653400_B6","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2984.2984","article-title":"Mutated MYD88 zygosity and CXCR4 mutation status are important determinants of ibrutinib response and progression free survival in Waldenstrom\u2019s macroglobulinemia [abstract]","volume":"128","author":"Treon","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2020021108322653400_B7","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.24086","article-title":"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011","volume":"90","author":"Al-Hamadani","year":"2015","journal-title":"Am J Hematol"},{"issue":"20","key":"2020021108322653400_B8","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2020021108322653400_B9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"364","key":"2020021108322653400_B10","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"6","key":"2020021108322653400_B11","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"2020021108322653400_B12","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2020021108322653400_B13","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/hon.2380","article-title":"Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma-a \u201creal world\u201d study","volume":"35","author":"Epperla","year":"2017","journal-title":"Hematol Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/4\/500\/1631111\/advances029058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/4\/500\/1631111\/advances029058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T13:58:57Z","timestamp":1581429537000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/4\/500\/246745\/Resistance-mechanism-for-ibrutinib-in-marginal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,2,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018029058","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,13]]}}}